CD274 and neoplasm: Although the blockage of the PD-1/PD-L1 axis has elicited durable clinical responses in many patients, only 10–40% show clinical response to monotherapy, pointing out the possibility that alternative pathways may have significant impact on the antitumor immune activity in patients with various tumour types [1,2].